Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2017/09/009856
CTRI/2017/09/009856
Suspended
未知

Health Assessment and clinical study on the effect of Shatavari in perimenopausal women : A pilot study

Charutar Vidya Mandal0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: null- Pre menopausal, menopausal and postmenopausal patients

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: null- Pre menopausal, menopausal and postmenopausal patients
Sponsor
Charutar Vidya Mandal
Status
Suspended
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
Charutar Vidya Mandal

Eligibility Criteria

Inclusion Criteria

  • •Female patients above 40 years will be divided into three groups as pre menopausal, menopasual and postmenopausal according to their signs and symptoms with change in menstrual pattern.

Exclusion Criteria

  • •Patient unwilling to participate in the study. Life threatening illness like renal disorders and malignancy.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A Study of RoActemra/Actemra (tocilizumab) in Comparison to Enbrel (etanercept) in Patients With Rheumatoid Arthritis and Increased Risk for Heart Disease.Rheumatoid ArthritisMedDRA version: 14.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2010-020065-24-ESF. Hoffmann-La Roche Ltd.2,800
Active, not recruiting
Phase 1
A Study of RoActemra/Actemra (tocilizumab) in Comparison to Enbrel (etanercept) in Patients With Rheumatoid Arthritis and Increased Risk for Heart Disease.Rheumatoid ArthritisMedDRA version: 16.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2010-020065-24-BEF. Hoffmann-La Roche Ltd.3,080
Active, not recruiting
Phase 1
A Study of RoActemra/Actemra (tocilizumab) in Comparison to Enbrel (etanercept) in Patients With Rheumatoid Arthritis and Increased Risk for Heart Disease.Rheumatoid ArthritisMedDRA version: 14.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2010-020065-24-GRF. Hoffmann-La Roche Ltd.2,800
Active, not recruiting
Phase 1
A Study of RoActemra/Actemra (tocilizumab) in Comparison to Enbrel (etanercept) in Patients With Rheumatoid Arthritis and Increased Risk for Heart Disease.Rheumatoid ArthritisMedDRA version: 17.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2010-020065-24-ATF. Hoffmann-La Roche Ltd.3,080
Active, not recruiting
Phase 1
A Study of RoActemra/Actemra (tocilizumab) in Comparison to Enbrel (etanercept) in Patients With Rheumatoid Arthritis and Increased Risk for Heart Disease.Rheumatoid ArthritisMedDRA version: 18.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2010-020065-24-LVF. Hoffmann-La Roche Ltd.3,080